Genfit S.A. (GNFTP.XC)
| Previous close | 3.1850 |
| Open | 3.1850 |
| Bid | 3.4450 x N/A |
| Ask | 3.5050 x N/A |
| Day's range | 3.1850 - 3.1850 |
| 52-week range | 3.1850 - 3.9700 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 158.807M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024. GENFIT accelerates its research in Acute on-Chronic Liver Failure (ACLF) EF CLIF and GENFIT partnership event GENFIT will co-host an event with the European Foundation for the Study
- Globe Newswire
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
Quorum of 27.25% on first convening; allowing approval of all the resolutions Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 22, 2024. The quorum on first convening amounted to 27.25% and sharehol
- GlobeNewswire
GENFIT Reports First Quarter 2024 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.1 Cash position As of March 31, 2024, the Company’s cash and cash equivalents amounted to €74.0 million compared with €128.6 million as
